The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1159
June 23, 2003
View Complete Issue         Table of Contents 2019 
Enfuvirtide (Fuzeon) for HIV infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Enfuvirtide (Fuzeon) for HIV infection
June 23, 2003 (Issue: 1159)
Enfuvirtide (T-20; Fuzeon Trimeris/Roche), the first in a new class of HIV drugs known as fusion inhibitors, has received accelerated approval from the FDA for use with other antiretrovirals in adults and children with viral replication despite...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Enfuvirtide (Fuzeon) for HIV infection
Article code: 1159a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.